Literature DB >> 9302745

A systematic method for evaluating the potential viability of local vaccine producers.

J Milstien1, A Batson, W Meaney.   

Abstract

Vaccine production exists in > 55 countries, but many production facilities cannot assure a reliable supply of existing or new vaccines. By analysing the characteristics of successful producers, we have identified seven critical elements for viability, each defined by several indicators. Each indicated weakness implies an investment to correct it. Thirty-one manufacturers were assessed based on these viability indicators and the implied investment costs. Three general groupings were found. 'Viable' producers scored well in all seven categories. Those with a 'low probability' of viability are weak in all areas. Facilities regarded as 'potentially viable' may produce sufficient vaccine to meet national needs, but must develop appropriate structures to effectively manage change. This analysis provides a logical system for governments and donors to evaluate the potential effectiveness of further investment in local vaccine production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302745     DOI: 10.1016/s0264-410x(97)00053-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  An updated methodology to review developing-country vaccine manufacturer viability.

Authors:  Nicholas Luter; Ritu Kumar; Dai Hozumi; Tina Lorenson; Shannon Larsen; Bhavya Gowda; Amie Batson
Journal:  Vaccine       Date:  2017-06-09       Impact factor: 3.641

Review 2.  The complexity and cost of vaccine manufacturing - An overview.

Authors:  Stanley Plotkin; James M Robinson; Gerard Cunningham; Robyn Iqbal; Shannon Larsen
Journal:  Vaccine       Date:  2017-06-21       Impact factor: 3.641

3.  Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approach.

Authors:  David Manheim; Derek Foster
Journal:  F1000Res       Date:  2020-09-18

Review 4.  Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review).

Authors:  Daniela Calina; Anca Oana Docea; Demetrios Petrakis; Alex M Egorov; Aydar A Ishmukhametov; Alexsandr G Gabibov; Michael I Shtilman; Ronald Kostoff; Félix Carvalho; Marco Vinceti; Demetrios A Spandidos; Aristidis Tsatsakis
Journal:  Int J Mol Med       Date:  2020-05-06       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.